| Trial ID: | L4660 |
| Source ID: | NCT06313008
|
| Associated Drug: |
Empagliflozin 10 Mg
|
| Title: |
Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Coronary Artery Disease|Type 2 Diabetes
|
| Interventions: |
DRUG: Empagliflozin 10 MG|DRUG: Vildagliptin 50 MG
|
| Outcome Measures: |
Primary: LVEF %, echocardiographic measurements, 6 months|Sortilin (ng/ml), Serum Biomarkers, 6 months|LDL (mg/dl), Lipid profile, 6 months | Secondary: hsCRP (mg/L), Serum Biomarkers, 6 months|HbA1c %, Glycemic control, 6 months|FBG (mg/dl), Serum level, 6 Months
|
| Sponsor/Collaborators: |
Sponsor: Damanhour University | Collaborators: Tanta University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
120
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2023-08-10
|
| Completion Date: |
2024-10-10
|
| Results First Posted: |
|
| Last Update Posted: |
2024-11-29
|
| Locations: |
Rehab Hussein Werida, Damanhūr, Elbehairah, 31527, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT06313008
|
